Type I Framework Complex: Photocontrolled Superoxide Anion Generator.

IF 10.7 1区 综合性期刊 Q1 Multidisciplinary
Research Pub Date : 2026-04-27 eCollection Date: 2026-01-01 DOI:10.34133/research.1262
Zehao Jing, Yingying Zhang, Yingnan Wu, Xiaoqiang Chen, Meizhen Yin, Mingle Li, Xiaojun Peng
{"title":"Type I Framework Complex: Photocontrolled Superoxide Anion Generator.","authors":"Zehao Jing, Yingying Zhang, Yingnan Wu, Xiaoqiang Chen, Meizhen Yin, Mingle Li, Xiaojun Peng","doi":"10.34133/research.1262","DOIUrl":null,"url":null,"abstract":"<p><p>Photodynamic therapy (PDT) is a clinically approved therapeutic modality that uses photosensitizers (PSs) to generate reactive oxygen species (ROS) upon light irradiation, enabling disease treatment with minimal invasiveness and excellent spatiotemporal precision. Despite these advantages, conventional PDT is fundamentally constrained by the mismatch between its oxygen dependence and the intrinsically hypoxic tumor microenvironment, which markedly compromises therapeutic outcomes. In this context, type I PSs offer a promising solution because they can produce cytotoxic radicals through electron transfer pathways, thereby reducing dependence on oxygen (O<sub>2</sub>) and improving efficacy under hypoxic conditions. Organic framework materials have recently emerged as powerful and versatile platforms for constructing type I PSs, owing to their programmable structures, high porosity, and efficient photoinduced charge separation and electron transfer. Importantly, the modular nature of these frameworks enables rational tuning of both structural motifs and compositional building blocks, allowing systematic regulation of light absorption, redox properties, and ROS generation pathways to maximize type I PDT performance. Moreover, organic frameworks can simultaneously function as nanocarriers for therapeutics, facilitating co-delivery and synergistic combinations (e.g., chemotherapy, immunotherapy, or catalytic therapies) that may achieve more durable and comprehensive tumor control. However, current studies remain fragmented, and there is still a lack of an integrated and mechanistically grounded overview that connects framework design principles with type I ROS generation mechanisms and performance optimization strategies. To address this unmet need, this review provides a comprehensive summary of the design strategies, mechanistic insights, and recent progress in organic framework-based type I PSs. We first outline the fundamental principles of type I photochemistry and the key physical and chemical processes underlying type I PDT. We then highlight rational design and modulation strategies to enhance optical properties, promote charge separation, and strengthen oxygen independence. Next, we summarize representative in vivo/in vitro disease models to demonstrate emerging diagnostic and therapeutic applications. Finally, we discuss current challenges and future opportunities for clinical translation, offering practical guidance for the development of next-generation phototherapeutic agents based on these innovative framework systems.</p>","PeriodicalId":21120,"journal":{"name":"Research","volume":"9 ","pages":"1262"},"PeriodicalIF":10.7000,"publicationDate":"2026-04-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13113325/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Research","FirstCategoryId":"103","ListUrlMain":"https://doi.org/10.34133/research.1262","RegionNum":1,"RegionCategory":"综合性期刊","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2026/1/1 0:00:00","PubModel":"eCollection","JCR":"Q1","JCRName":"Multidisciplinary","Score":null,"Total":0}
引用次数: 0

Abstract

Photodynamic therapy (PDT) is a clinically approved therapeutic modality that uses photosensitizers (PSs) to generate reactive oxygen species (ROS) upon light irradiation, enabling disease treatment with minimal invasiveness and excellent spatiotemporal precision. Despite these advantages, conventional PDT is fundamentally constrained by the mismatch between its oxygen dependence and the intrinsically hypoxic tumor microenvironment, which markedly compromises therapeutic outcomes. In this context, type I PSs offer a promising solution because they can produce cytotoxic radicals through electron transfer pathways, thereby reducing dependence on oxygen (O2) and improving efficacy under hypoxic conditions. Organic framework materials have recently emerged as powerful and versatile platforms for constructing type I PSs, owing to their programmable structures, high porosity, and efficient photoinduced charge separation and electron transfer. Importantly, the modular nature of these frameworks enables rational tuning of both structural motifs and compositional building blocks, allowing systematic regulation of light absorption, redox properties, and ROS generation pathways to maximize type I PDT performance. Moreover, organic frameworks can simultaneously function as nanocarriers for therapeutics, facilitating co-delivery and synergistic combinations (e.g., chemotherapy, immunotherapy, or catalytic therapies) that may achieve more durable and comprehensive tumor control. However, current studies remain fragmented, and there is still a lack of an integrated and mechanistically grounded overview that connects framework design principles with type I ROS generation mechanisms and performance optimization strategies. To address this unmet need, this review provides a comprehensive summary of the design strategies, mechanistic insights, and recent progress in organic framework-based type I PSs. We first outline the fundamental principles of type I photochemistry and the key physical and chemical processes underlying type I PDT. We then highlight rational design and modulation strategies to enhance optical properties, promote charge separation, and strengthen oxygen independence. Next, we summarize representative in vivo/in vitro disease models to demonstrate emerging diagnostic and therapeutic applications. Finally, we discuss current challenges and future opportunities for clinical translation, offering practical guidance for the development of next-generation phototherapeutic agents based on these innovative framework systems.

I型框架复合物:光控超氧阴离子发生器。
光动力疗法(PDT)是一种临床批准的治疗方式,它利用光敏剂(ps)在光照射下产生活性氧(ROS),使疾病治疗具有最小的侵入性和优异的时空精度。尽管有这些优势,传统PDT从根本上受到其氧依赖性与内在缺氧肿瘤微环境之间不匹配的限制,这明显影响了治疗效果。在这种情况下,I型ps提供了一个很有前途的解决方案,因为它们可以通过电子转移途径产生细胞毒自由基,从而减少对氧(O2)的依赖,提高在缺氧条件下的疗效。有机骨架材料由于其可编程结构、高孔隙率和高效的光诱导电荷分离和电子转移,近年来成为构建I型ps的强大而通用的平台。重要的是,这些框架的模块化特性能够合理调整结构基元和组成构建块,允许系统地调节光吸收、氧化还原特性和ROS生成途径,以最大限度地提高I型PDT性能。此外,有机框架可以同时作为治疗的纳米载体,促进共递送和协同组合(例如,化疗,免疫治疗或催化治疗),从而实现更持久和全面的肿瘤控制。然而,目前的研究仍然是零散的,并且仍然缺乏将框架设计原则与I型ROS生成机制和性能优化策略联系起来的综合和机械基础概述。为了解决这一未满足的需求,本文综述了基于有机框架的I型ps的设计策略、机理见解和最新进展。我们首先概述了I型光化学的基本原理和I型PDT的关键物理和化学过程。然后,我们强调了合理的设计和调制策略,以提高光学性质,促进电荷分离,并加强氧独立性。接下来,我们总结了具有代表性的体内/体外疾病模型,以展示新兴的诊断和治疗应用。最后,我们讨论了临床转化的当前挑战和未来机遇,为基于这些创新框架系统的下一代光治疗剂的开发提供了实践指导。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Research
Research Multidisciplinary-Multidisciplinary
CiteScore
13.40
自引率
3.60%
发文量
0
审稿时长
14 weeks
期刊介绍: Research serves as a global platform for academic exchange, collaboration, and technological advancements. This journal welcomes high-quality research contributions from any domain, with open arms to authors from around the globe. Comprising fundamental research in the life and physical sciences, Research also highlights significant findings and issues in engineering and applied science. The journal proudly features original research articles, reviews, perspectives, and editorials, fostering a diverse and dynamic scholarly environment.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信
小红书